NCT06015880View on ClinicalTrials.gov

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

June 29, 2026

Study Completion Date

June 29, 2026

Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Mosunetuzumab

Given IV

DRUG

Polatuzumab Vedotin

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (7)

22908

RECRUITING

University of Virginia Cancer Center, Charlottesville

27157

RECRUITING

Wake Forest University Health Sciences, Winston-Salem

33612

SUSPENDED

Moffitt Cancer Center, Tampa

60611

RECRUITING

Northwestern University, Chicago

73104

RECRUITING

University of Oklahoma Health Sciences Center, Oklahoma City

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH